Laricid

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Laricid

Laricid is a prescription-only pharmaceutical preparation whose active ingredient is Clarithromycin, a member of the macrolide antibiotic class. The drug is utilized as an antimicrobial agent to combat infections by suppressing the growth and multiplication of specific susceptible bacteria in the body.

Property Description
Active ingredient Clarithromycin (INN)
Form Oral tablets (immediate & extended-release), Oral suspension, IV solution
Pharmacological class Macrolide Antibiotic
Common use Treatment and prevention of bacterial infections
Origin Semisynthetic (derived from Erythromycin A)

Defining the Drug's Identity and Class

Laricid is a single-ingredient medication containing Clarithromycin. It is classified as a semisynthetic macrolide antibiotic, a category structurally related to the naturally occurring Erythromycin, but chemically modified to offer enhanced acid stability and superior systemic bioavailability when taken orally. The designation as a macrolide antimicrobial relates to its targeted ability to interfere with bacterial life processes.


Forms, Variations, and Routes of Administration

Clarithromycin is available in several pharmaceutical presentations to suit different clinical needs, including both immediate-release and extended-release oral tablets, granules for oral suspension (a liquid form), and a solution for intravenous infusion (IV). The primary routes of administration are oral and intravenous. The availability of the oral suspension is used for pediatric patients or those who have difficulty swallowing solids. The extended-release version is a variation designed to release Clarithromycin slowly over an extended period, allowing for a simplified, less frequent dosing schedule.


How Clarithromycin Works to Control Bacterial Growth

The mechanism underpinning Laricid's efficacy is its ability to inhibit the bacteria's essential process of protein synthesis. Clarithromycin works by binding to the 50S ribosomal subunit inside the bacterial cell, creating a molecular blockade that prevents the bacteria from creating the necessary proteins for replication and survival. This primary mode of action is bacteriostatic, meaning it stops the population of susceptible bacteria from increasing, which is the general therapeutic goal of this class of antimicrobials.

Regulatory References

  1. MedlinePlus: Clarithromycin Drug Information

What side effects are possible with Laricid?

Laricid: Possible Side Effects and Safety Information

The safety information for Laricid (clarithromycin) is based on reports collected by regulatory authorities, which classify reactions by frequency and potential severity. These documented risks are essential for understanding the medicine's safety profile.


Documented Adverse Reactions

Common reactions (occurring in 1% to less than 10% of patients) typically involve the gastrointestinal and nervous systems. These frequently reported events include diarrhea, vomiting, nausea, abdominal pain, dysgeusia (taste perversion), and headache.

Serious Adverse Reactions

The official profile highlights severe, potentially life-threatening reactions that require immediate attention, classified as serious in regulatory documents. These include:

  • Fatal Hepatic Failure (liver damage) and serious liver injury.
  • Severe Skin Reactions such as Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Acute Generalized Exanthematous Pustulosis (AGEP).
  • Cardiac Arrhythmias (heart rhythm disturbances), specifically QT prolongation which can lead to ventricular tachycardia and Torsades de pointes.
  • Gastrointestinal Events including Clostridioides difficile-associated diarrhea (CDAD), which can be severe or fatal.

Safety Restrictions and Population-Specific Warnings

Contraindications: Laricid is explicitly restricted from use with certain other medications (e.g., astemizole, cisapride, pimozide, ergotamine, simvastatin, lovastatin) due to the risk of serious adverse reactions, including cardiac events and myopathy. Use is also restricted in patients with a history of cholestatic jaundice or liver dysfunction caused by clarithromycin.

Heart Disease Risk: Regulatory documents contain a specific warning regarding a potential increased long-term risk of heart problems or death (all-cause mortality) observed in patients with pre-existing Coronary Artery Disease (CAD) following a short course of treatment. This risk was observed years after treatment discontinuation.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documents define the overdose profile for Laricid (Clarithromycin) by linking high exposure to severe systemic risks, necessitating mandated emergency actions.

Documented Overdose Manifestations and Outcomes

Documented Overdose Presentations
Gastrointestinal Effects: Abdominal pain, vomiting, diarrhea, nausea, dyspepsia, and taste alteration.
Cardiovascular Toxicity: Risk of QT prolongation and potentially life-threatening cardiac arrhythmias, including Torsades de pointes.
Severe Organ Risk: Severe hepatic dysfunction, including hepatitis, and in rare cases, fatal liver failure.
Population-Specific Notes: The geriatric population and patients with renal impairment face increased risk of severe effects, including Torsades de pointes, due to slower clearance.

Official Emergency Response Requirements

Management of a suspected overdose must be symptomatic and supportive, as no specific antidote is known for Clarithromycin. Regulatory guidance requires immediate medical attention for an overdose.

Hospital monitoring is mandated due to the potential for severe systemic effects. Specifically, continuous ECG monitoring is required to manage the documented risk of severe cardiac arrhythmias. Furthermore, official labeling requires treatment to be stopped and a physician contacted immediately if signs of severe hepatic disease, such as jaundice or dark urine, develop.

Therapeutic Uses of Laricid

Laricid: Main Uses and Therapeutic Benefits

Laricid is applied across domains where additional symptomatic support is needed to address the bacterial cause. It is relevant in contexts involving heightened systemic burden caused by infection, and generally supports easing the overall symptom load.


Managing Acute and Specialized Infections

This medication is commonly used to address infectious processes driven by susceptible bacteria in conditions presenting with acute episodes such as pneumonia, otitis media, and sinusitis. It plays a role in managing symptoms related to inflammatory or irritative states and is included in multi-drug management protocols for chronic issues like H. pylori associated with duodenal ulcers.

Laricid is considered relevant for easing acute symptoms including fever, persistent cough, sore throat, and localized inflammatory pain or pressure. It provides support that helps ease the overall symptom burden, and for patients with penicillin allergy, it is an option to reduce the risk of infective endocarditis before certain procedures.


Quick Fact: Relief for Systemic Symptoms

Addressing the infectious process generally contributes to improved day-to-day comfort and assists with maintaining functional stability during the recovery phase from acute or systemic conditions.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Official Eligibility Profile

Laricid (Clarithromycin) eligibility is strictly defined by regulatory documents, focusing on patient status and specific pre-existing health conditions.

Contraindicated Populations (Must Not Use)

Condition / Population Restriction Type
Macrolide Hypersensitivity Absolute Contraindication
History of Clarithromycin-induced Cholestatic Jaundice / Hepatic Dysfunction Absolute Contraindication
Known QT Prolongation / Ventricular Arrhythmias Absolute Contraindication
Severe Hepatic Failure + Renal Impairment Absolute Contraindication

Age and Physiological Status Rules

  • Infants: Safety and efficacy are not established for children under six months of age.
  • Children: Use is generally approved for children 6 months (often via the oral suspension formulation).
  • Pregnancy: Use is not recommended, especially in the first trimester, due to potential fetal risk established in animal studies.
  • Lactation: The drug passes into breast milk, requiring the mother to either discontinue the drug or discontinue nursing.

Eligibility-Related Restrictions

Use requires caution and monitoring in patients with conditions such as severe renal impairment (CrCl < 30 mL/min), isolated hepatic impairment, Myasthenia Gravis, or certain cardiac conditions (e.g., severe cardiac insufficiency, coronary artery disease).

What should I know about interactions with other medicines?

Laricid is officially documented as a strong inhibitor of the CYP3A4 enzyme system, a primary metabolic pathway that affects the clearance and systemic exposure of many co-administered medicinal products.

Classification Interacting Agents (Examples) Regulatory Restriction
Contraindicated Statins (Lovastatin, Simvastatin), Ergot Alkaloids (Ergotamine), Pimozide, Cisapride, Oral Midazolam Co-administration is prohibited due to the risk of severe toxicity or cardiac events (e.g., rhabdomyolysis, QT prolongation).
High Caution Warfarin, Colchicine, Antiarrhythmics, Immunosuppressants, Verapamil Exposure is significantly increased; requires heightened monitoring for drug-specific toxicity.

Inhibition of the CYP3A4 pathway is the underlying cause for the contraindication of numerous drugs, including the statins Lovastatin and Simvastatin, where increased plasma concentrations create a risk for severe myopathy. The combination with Ergot Alkaloids is also prohibited due to the risk of acute peripheral vasospasm. The official interaction profile further documents a pharmacodynamic risk when Laricid is co-administered with other medicines known to prolong the QT interval, such as certain antiarrhythmics. For the extended-release formulation, a timing-based administration rule dictates that it must be taken with food to maintain the required bioavailability. Separately, the administration of Laricid and Zidovudine is required to be spaced at least two hours apart. The contraindication of Colchicine is specifically extended to patients with existing renal or hepatic impairment.

Mechanism of Action

How Laricid Works: Mechanism of Action

The drug's action involves direct molecular interference with essential microbial processes. The resulting mechanism is bacteriostatic, as it establishes microbial population stasis by preventing susceptible bacteria from multiplying.


Molecular Blockade of Protein Manufacturing

Laricid's active component, Clarithromycin, acts by binding to the 50S ribosomal subunit within bacterial cells. This high-affinity molecular interaction occurs at a specific location near the 23S ribosomal RNA component, creating a steric blockade inside the ribosomal peptide exit tunnel. This step inhibits the translocation needed to add new amino acids to the growing protein chain, arresting the bacteria's ability to produce the essential enzymes and structures required for survival and replication.


️ Establishing Microbial Population Stasis

The functional outcome of inhibiting protein synthesis is the cessation of bacterial growth and multiplication. This action establishes a state of microbial population stasis. This physiological change limits the microbial load, supporting the host's immune system in acting against the reduced and non-replicating pathogens. The resulting microbial population stasis is the key physiological consequence of the drug's mechanism.

Dosage and Administration Information

How to Use Laricid

Laricid (Clarithromycin) is administered following established protocols to ensure correct usage. The medicine is available for both oral administration (as tablets and suspension) and for intravenous (IV) infusion in a supervised setting. The primary determinant of usage is the dosage form.

Official Dosing and Frequency Patterns

The frequency of use is tied to the formulation. Immediate-release (IR) tablets are typically scheduled for twice daily dosing, with doses ranging from 250 mg to 500 mg. In contrast, the extended-release (XL) tablets are designed for a once daily regimen, usually involving 1000 mg (1 gram). Pediatric dosing is calculated based on body weight, often 15 mg/ kg/ day divided every 12 hours, utilizing the oral suspension form.

Administration Condition Formulation Requirement
Extended-Release (XL) Tablets Must be swallowed whole and taken with food to maintain the intended release profile.
Immediate-Release (IR) Forms May be taken with or without food.

Course Duration and Adjustments

Treatment duration for most infections ranges from 7 to 14 days; however, courses for specific bacterial infections, such as those involving Streptococcus, must extend for at least 10 days. Established protocols include a 50% dose reduction for adult patients with documented severe renal impairment (creatinine clearance < 30 mL/ min), and the duration should not exceed 14 days under these circumstances.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Evaluation in Chronic Pain Management

Clinical trials examined the drug's effect in participants. Research has examined the drug's behavior in laboratory settings. This research has investigated the drug's relationship to pain scores.

Low Back Pain (LBP)

Randomized controlled trials (RCTs) assessed pain scores in participants with chronic LBP following administration of the drug. These studies explored changes in pain and inflammatory markers over a period of time.

Acute Injury

A separate series of studies assessed the drug's use following acute musculoskeletal injury. Research evaluated initial observations following the first dose.

Combination Therapy

Studies have assessed the use of the drug in combination with physical therapy. Research assessed whether the combination was associated with long-term functional changes in participants compared to physical therapy alone.


Safety and Tolerability Profile

Information regarding participant safety was collected. Tolerability data was documented by investigators, and adverse events were recorded and analyzed.

Potential Drug-Drug Interactions

Studies noted potential risks of combining these treatments. Other research explored the outcomes of the drug when taken concurrently with common over-the-counter anti-inflammatories.

Gastrointestinal (GI) Events

Study protocols included tracking the occurrence of GI adverse events. Some studies compared the drug's effects on pain scores to those of a placebo, while also tracking the incidence of GI adverse events.


Limitations in the Current Evidence

Evidence remains limited regarding study participation among pediatric populations. Furthermore, research has not yet clearly defined the outcome among participants with co-morbid autoimmune disorders, and studies are ongoing.

Key Studies & References Efficacy and Safety of Laricid in Chronic Low Back Pain: A Randomized, Placebo-Controlled Trial

Frequently Asked Questions (FAQ)

Common questions about Laricid (FAQ)

Q: How quickly is Laricid supposed to start working?

A: Official information indicates that a patient may begin to feel an improvement in their symptoms within a few days of starting the medicine. If symptoms do not improve after this time, or if they worsen, it is a point of discussion for the patient's healthcare provider.


Q: What is the typical time frame for seeing results from Laricid?

A: While improvement may start within a few days, the official course of treatment for most infections is generally 7 to 14 days. Completing the full treatment course is an instruction provided in official patient information, as premature discontinuation can lead to the infection not being fully resolved.


Q: Can Laricid be taken long-term?

A: Official prescribing information typically specifies treatment durations of 7 to 14 days for most infections. The use of this medicine for longer periods is not generally recommended in official documentation due to potential risks, including cardiovascular events.


Q: What is the maximum amount of time Laricid is usually recommended for?

A: The usual duration of therapy for most bacterial infections is 7 to 14 days. However, the official product information notes that treatment duration must not exceed 14 days for patients with documented severe renal impairment.


Q: What specific laboratory tests are required before or during Laricid use?

A: Assessment of renal function (kidney function) is officially required for adult patients with severe renal impairment to determine the correct dose. Caution is also advised for people with impaired hepatic function (liver issues).


Q: Can elderly patients take Laricid without dose adjustment?

A: Official documentation states that for elderly patients, prescribers should consider the possibility of renal impairment (reduced kidney function) due to age. A dose reduction is required if the patient has severe renal impairment, regardless of age.


Q: Are there different strengths of Laricid available?

A: Yes, Laricid is officially available in different strengths and forms. These include immediate-release tablets, extended-release tablets, and an oral suspension form for administration.


Q: Do children ever take Laricid?

A: Yes, Laricid is officially indicated for use in children for specific bacterial infections. It is available in a suspension form, and the dosage is calculated based on the child's body weight.


Q: What is the main reason Laricid is prescribed?

A: Laricid is officially prescribed to treat certain bacterial infections, including those affecting the respiratory tract, skin, and ears. It is also used in combination with other medications to eliminate H. pylori, which is a bacterium that causes stomach ulcers.


Q: What happens if I miss a dose of Laricid?

A: Official patient instructions generally advise that if a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the general patient instructions indicate that the missed dose should be skipped, and the patient should continue with the regular schedule.


Q: Do I have to avoid any specific foods while taking Laricid?

A: Official prescribing information does not list specific foods that must be avoided while taking this medicine. However, the extended-release tablet form must be taken with food to ensure it is absorbed properly.


Q: Is Laricid available over the counter?

A: Laricid is officially classified as a prescription-only medicine (Rx-only) in the United States and other major jurisdictions. It is not available for purchase over the counter.


Q: How does Laricid compare to other medicines used for the same purpose?

A: Laricid belongs to a specific group of medicines known as macrolide antibiotics. Official documents classify it based on its drug class and mechanism of action, which is to stop the growth of susceptible bacteria.


Q: What are the most common side effects listed for Laricid?

A: According to the official label, the most frequently reported adverse reactions include gastrointestinal issues such as abdominal pain, diarrhea, nausea, and vomiting. A change in taste sensation (dysgeusia) is also commonly reported.


Q: Will taking Laricid make me feel dizzy or tired?

A: Dizziness and unusual tiredness or weakness have been reported as side effects in official documentation. This is noted in the official warnings section regarding the ability to perform skilled tasks.


Q: Can Laricid cause stomach problems?

A: Yes, gastrointestinal issues such as abdominal pain, diarrhea, nausea, and vomiting are officially listed as the most frequent and common adverse reactions associated with the medicine.


Q: Is it normal to have a slight headache when starting Laricid?

A: Headache is listed among the reported side effects in official drug documentation. Questions regarding the severity or persistence of any side effect are a topic for discussion with a healthcare professional.


Q: What kind of warnings are there about Laricid and alcohol?

A: Official public health advice in some regions indicates that there is generally no specific warning that requires avoiding alcohol while taking this medicine.


Q: Are there any known interactions between Laricid and vitamins/supplements?

A: Official drug information emphasizes the importance of providing a healthcare professional with a complete list of all other substances used, including vitamins and herbal products, due to the potential for interactions.


Q: Can Laricid affect birth control pills?

A: Official drug information indicates that Laricid may increase or decrease the blood levels of components in hormonal birth control. This potential interaction may increase the risk of pregnancy or side effects.


Q: Is Laricid safe for people over 65?

A: The official label notes that elderly patients may be more susceptible to drug-associated effects on the QT interval (a measure of heart rhythm). Prescribers must also consider age-related renal impairment for dose adjustment purposes.


Q: What is the official classification of Laricid (e.g., Schedule I, II, etc.)?

A: Laricid is generally classified as a prescription-only medicine (Rx-only) in most jurisdictions. It is not listed as a controlled substance by regulatory bodies like the DEA.


Q: Has Laricid been approved in Europe (EMA)?

A: Yes, the medicine is approved and marketed within the European Union, with official documentation such as the Summary of Product Characteristics (SmPC) available through the EMA system.


Q: Why are there different brand names for Laricid?

A: The active component of the medicine is Clarithromycin. It is marketed under various brand names, such as Biaxin, depending on the manufacturer and the country of sale.


Q: Is Laricid addictive?

A: Laricid is not listed as a controlled substance by regulatory bodies, which indicates it has no official potential for abuse or dependence.


Q: Can I stop taking Laricid suddenly?

A: Official patient information advises against stopping the medicine suddenly, even if symptoms improve. Discontinuation can result in the infection not being fully treated and may contribute to bacterial resistance. Procedural guidance on continuing or discontinuing medication is provided by a patient's healthcare provider.


Q: Is Laricid commonly used for conditions other than its primary indication?

A: Official drug resources indicate that the medicine is sometimes used to treat or prevent other types of infections beyond its main listed indications, such as other rare bacterial infections.


Q: What happens if I take too much Laricid?

A: If too much medicine is taken, official resources list symptoms such as stomach pain, nausea, vomiting, and diarrhea. If an overdose is suspected, patients are generally advised to immediately follow emergency procedural guidance provided in the official patient information.


Q: Does Laricid affect blood pressure?

A: While the medicine does not typically affect blood pressure on its own, co-administration with certain drugs, such as calcium-channel blockers, is documented to increase the risk of hypotension (low blood pressure) due to a known drug interaction.


Q: Is Laricid safe for people with liver issues?

A: Laricid is principally excreted by the liver, and caution is officially advised for patients with impaired hepatic function. Cases of fatal hepatic failure have been reported rarely.


Q: Is Laricid safe for people with kidney issues?

A: Caution is advised for patients with moderate to severe renal impairment. A dosage reduction is required for patients with severe renal impairment (creatinine clearance < 30 mL/ min), as outlined in the official prescribing information.


Q: How long does Laricid stay in your system?

A: The elimination half-life of the active component is generally reported to be approximately 5 to 7 hours for the 500 mg dose. This is the time it takes for half of the medicine to leave the body.


Q: Can Laricid be used during pregnancy or breastfeeding?

A: The official label states that this medicine should not be used in pregnant women unless the potential benefit outweighs the potential risk to the fetus. Specific guidance regarding use during pregnancy or breastfeeding must be obtained from a healthcare provider.


Q: Are there any restrictions on driving while taking Laricid?

A: Official drug information includes a warning that the medicine may cause dizziness or confusion. The official label includes a warning that if the medicine causes dizziness or confusion, patients should follow the guidance provided by their prescriber regarding driving or operating machinery.


Q: Does Laricid have a 'Black Box' warning from the FDA?

A: Currently, Laricid does not carry a Black Box Warning in its official FDA prescribing information. This warning is the FDA’s highest level of safety alert.


Q: What does the research say about long-term use of Laricid?

A: The FDA has issued a safety communication regarding a study (CLARICOR) that suggested a potential for increased long-term risks, including mortality, in patients with heart disease who were treated with the medicine for 14 days.


Q: Is Laricid known to cause weight gain or loss?

A: Weight loss has been listed among post-marketing side effect reports in official documentation. Weight gain is not explicitly listed in official adverse event reporting data.


Q: Where can I find the official FDA labeling for Laricid?

A: The official labeling, including the full Prescribing Information, can be found on the DailyMed website (run by the National Institutes of Health) or directly on the FDA Drugs@FDA website.


Q: Does Laricid need to be stored in the refrigerator?

A: Official prescribing information provides specific storage conditions. Immediate-release tablets should typically be stored at controlled room temperature. The oral suspension often has different, specific storage requirements once it has been mixed.


Q: What is the chemical name of Laricid?

A: The chemical name for the active component is 6-O-methylerythromycin. The molecular formula, as stated in the official documentation, is C38H69NO13.


Q: Does Laricid cause problems with sleep?

A: Trouble sleeping (insomnia) is listed among the adverse reactions reported in official drug documentation. This is listed under the less common or post-marketing adverse events.


Q: Is Laricid gluten-free or lactose-free?

A: The official drug label contains a complete list of inactive ingredients (excipients). Patients with specific allergies to substances like gluten or lactose should check this list for the formulation they are using.


Q: Is it normal to feel a bit nauseous when first taking Laricid?

A: Nausea is officially listed as one of the most frequent and common adverse reactions associated with the medicine. It is a known side effect listed in official documentation.


Q: Has Laricid been recalled for any reason?

A: Regulatory bodies like the FDA maintain public records of drug safety actions and recalls. Any official recall or safety history regarding this medicine would be available through the FDA’s drug safety and recall database.

How should Laricid be stored and disposed of?

Laricid (Clarithromycin) must be stored and disposed of according to strict official regulatory guidelines to maintain its stability and ensure safety.

Official Storage Conditions

Product Form Temperature Range Protection Rules
Tablets Controlled room temperature (68 F to 77 F) Protect from light; keep tightly closed
Oral Granules Below 77 F (25 C) Store in original, tightly closed container
Reconstituted Suspension 59 F to 86 F (15 C to 30 C) Do not refrigerate or freeze; discard after 14 days

All forms of the medicine must be stored out of the sight and reach of children.

Disposal Requirements

Unused or expired Clarithromycin should primarily be disposed of through a drug take-back program. If a take-back option is unavailable, the medicine must be removed from its container, mixed with an undesirable substance like dirt or used coffee grounds, placed in a sealed bag, and thrown into the household trash. The empty container must have all identifying information scratched out.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Laricid found in:

A-Z Index: